36.3 Acute Liver Injury & Viral Hepatitis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

36.3 Acute Liver Injury & Viral Hepatitis

Key Takeaways Explain This Topic AI

Biochemical patterns of liver injury are classified by the R-value ([ALT/ULN] / [ALP/ULN]): R >=5 indicates a hepatocellular pattern, R <=2 indicates a cholestatic pattern, and R 2-5 indicates a mixed pattern; an AST:ALT ratio >=2:1 strongly suggests alcohol-induced liver disease, whereas extreme transaminitis (>1,000 to >5,000 U/L) narrows the differential to acute viral hepatitis, ischemic hepatitis ('shock liver'), or toxin/acetaminophen ingestion.

Serum transaminases (AST, ALT) reflect hepatocyte membrane injury and lysis, not synthetic capacity; acute hepatic synthetic failure is evaluated by Prothrombin Time / International Normalized Ratio (PT/INR), which rises within hours due to the short 4-to-6-hour half-life of Factor VII, whereas albumin has a ~20-day half-life and remains normal in acute injury.

Acute Liver Failure (fulminant hepatic failure) is strictly defined by acute liver injury with coagulopathy (INR >=1.5) AND hepatic encephalopathy in a patient without underlying cirrhosis; its presence mandates immediate transfer to an intensive care unit at a liver transplant center.

In acetaminophen toxicity, the toxic intermediate NAPQI depletes glutathione and causes centrilobular necrosis; risk is evaluated with the Rumack-Matthew nomogram plotted from a 4-hour serum APAP level, and N-acetylcysteine (NAC) should be administered immediately (optimally within 8 hours, but indicated at any time if APAP is detectable or transaminases are elevated).

In acute Hepatitis B, 95% of immunocompetent adults clear HBsAg spontaneously and develop immunity, whereas 90% of perinatally infected neonates develop chronic infection; acute Hepatitis E infection carries a catastrophic 15% to 25% mortality rate in pregnant women due to rapidly progressive fulminant hepatic failure.

Last updated: September 2026

Biochemical Patterns of Liver Injury & The R-Value Framework

Abnormal liver biochemistries are frequently encountered in primary care. To avoid diagnostic confusion, the clinician must distinguish between tests reflecting hepatocyte integrity (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), tests reflecting cholestasis and biliary secretion (alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT], and bilirubin), and tests reflecting true hepatic synthetic function (prothrombin time / international normalized ratio [PT/INR] and serum albumin).

The R-Value Formulation & Classification

The initial branching point in evaluating acute liver injury is determining whether the primary injury is hepatocellular, cholestatic, or mixed, quantified using the R-value (also known as the alanine aminotransferase to alkaline phosphatase ratio): R-Value = Serum ALT / Upper Limit of Normal (ULN) for ALT Serum ALP / Upper Limit of Normal (ULN) for ALP \text{R-Value} = \frac{\text{Serum ALT} / \text{Upper Limit of Normal (ULN) for ALT}}{\text{Serum ALP} / \text{Upper Limit of Normal (ULN) for ALP}} R-Value = Serum ALP / Upper Limit of Normal (ULN) for ALP Serum ALT / Upper Limit of Normal (ULN) for ALT ​

Hepatocellular Pattern (R >= 5.0) :

Characterized by marked, disproportionate elevation of ALT and AST relative to ALP.

Reflects primary hepatocyte necrosis, inflammation, or membrane leakage.

Cholestatic Pattern (R <= 2.0) :

Characterized by disproportionate elevation of ALP (and GGT) relative to ALT/AST.

Reflects impaired bile formation, canalicular transport defects, or mechanical biliary obstruction.

Mixed Pattern (R between 2.0 and 5.0) :

Concurrent hepatocyte necrosis and canalicular epithelial injury; common in drug-induced liver injury (DILI).

Differential Diagnosis of Extreme Transaminitis (>1,000 to >5,000 U/L)

While mild transaminitis (<300–500 U/L) has a broad differential (NAFLD, chronic viral hepatitis, alcohol, celiac disease, medications), massive transaminitis exceeding 1,000 U/L (and often reaching 2,000 to 10,000+ U/L) narrows the differential diagnosis to five major conditions :

Ischemic Hepatitis ('Shock Liver') :

Precipitated by transient profound systemic hypotension, cardiac arrest, cardiogenic shock, severe sepsis, or severe hypoxemia.

Features an abrupt, explosive rise in AST and ALT (often >3,000–5,000 U/L) accompanied by an extraordinarily high serum Lactate Dehydrogenase (LDH) level (LDH:ALT ratio typically >1.5).

Followed by an equally rapid, dramatic fall in transaminases (50% reduction every 24 to 72 hours) once hemodynamic stability is restored.

Toxin- & Acetaminophen (APAP)-Induced Hepatotoxicity :

Intentional or accidental acetaminophen overdose, Amanita phalloides (death cap mushroom) poisoning, carbon tetrachloride, or herbal supplements (kava, germander).

Acute Viral Hepatitis :

Acute Hepatitis A, acute Hepatitis B, acute Hepatitis E, and rarely acute Hepatitis C, Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), or Herpes Simplex Virus (HSV) hepatitis.

Acute Autoimmune Hepatitis (AIH) :

Severe acute presentation characterized by marked hypergammaglobulinemia (elevated IgG) and positive autoantibodies (Antinuclear Antibodies [ANA], Anti-Smooth Muscle Antibodies [ASMA], or Anti-Liver Kidney Microsome 1 [anti-LKM1]).

Acute Budd-Chiari Syndrome :

Acute thrombosis of the hepatic veins or inferior vena cava, causing severe sinusoidal congestion, ischemic centrilobular necrosis, painful hepatomegaly, and new-onset ascites.

The De Ritis Ratio (AST:ALT Ratio)

In Most Acute Hepatocellular Injuries (Viral Hepatitis, Ischemia, DILI) :

ALT is greater than AST (AST:ALT ratio < 1.0) . ALT is localized exclusively in the hepatocyte cytoplasm and has a substantially longer serum half-life (~47 hours) than AST (~17 hours).

In Alcohol-Induced Liver Disease (Alcoholic Hepatitis) :

AST:ALT Ratio >= 2.0 (with AST typically <300–500 U/L) .

Pathophysiologic Mechanisms :

Alcohol is a direct mitochondrial toxin, causing selective mitochondrial membrane rupture and releasing mitochondrial AST (mAST).

Chronic alcohol consumption induces severe hepatic deficiency of pyridoxal 5'-phosphate (vitamin B6) . Vitamin B6 is an obligatory coenzyme for both AST and ALT enzymatic synthesis, but ALT synthesis is far more sensitive to B6 depletion, severely blunting the liver's ability to produce and release ALT.

High-Yield Board Pearl : Serum transaminases in pure alcoholic hepatitis rarely exceed 500 U/L. If a heavy drinker presents with an AST or ALT >500 to 1,000 U/L, do NOT attribute it solely to alcohol ; immediately investigate for superimposed acetaminophen toxicity, ischemic hepatitis, or viral hepatitis!

Cholestatic Pattern: Alkaline Phosphatase & GGT Evaluation

Confirming Hepatic Origin : Alkaline phosphatase is produced by hepatocytes, bone osteoblasts, the placenta (in pregnancy), and the ileal mucosa. Elevated ALP must be confirmed as hepatic in origin by checking Gamma-Glutamyl Transferase (GGT) or 5'-nucleotidase. GGT is NOT elevated in bone disorders.

Imaging Workup : Transabdominal ultrasound is the mandatory first step to evaluate for intrahepatic versus extrahepatic ductal dilatation:

Ductal Dilatation Present : Extrahepatic mechanical obstruction (choledocholithiasis, pancreatic head adenocarcinoma, cholangiocarcinoma).

Ductal Dilatation Absent : Intrahepatic cholestasis:

Primary Biliary Cholangitis (PBC) : Autoimmune destruction of interlobular bile ducts in middle-aged women; positive Anti-Mitochondrial Antibodies (AMA) , elevated IgM, fatigue, pruritus; treated with oral ursodeoxycholic acid (UDCA).

Primary Sclerosing Cholangitis (PSC) : Fibro-obliterative destruction of intra- and extrahepatic bile ducts; 'beaded' appearance on MRCP; strongly associated with Ulcerative Colitis (in 70-80%); positive p-ANCA.

Drug-Induced Cholestasis : Amoxicillin-clavulanate is the single most common cause of idiosyncratic drug-induced cholestatic liver injury in clinical practice (often appearing 2 to 6 weeks after completing therapy); other culprits include anabolic steroids, oral contraceptives, erythromycin, and chlorpromazine.

• Evaluating Hepatic Synthetic Function & Acute Liver Failure (ALF)
• True Hepatic Synthetic Function Markers

Transaminases (AST, ALT) measure cell death, not organ function. The liver can lose 80% of its parenchyma while transaminases drop to normal as hepatocytes burn out.

Prothrombin Time / International Normalized Ratio (PT/INR) :

The earliest and most sensitive indicator of acute hepatic synthetic failure!

The liver synthesizes all coagulation factors except Factor VIII (produced by endothelial cells). Factor VII has the shortest biological half-life of any clotting factor (only 4 to 6 hours) .

A sudden decline in hepatic synthetic function depletes circulating Factor VII within hours, rapidly prolonging the PT and elevating the INR.

Serum Albumin :

Albumin is synthesized exclusively by the liver, but has a long serum half-life of approximately 20 days .

Consequently, in acute liver injury, acute viral hepatitis, or acetaminophen poisoning, serum albumin remains completely normal ! Hypoalbuminemia reflects chronic liver disease (cirrhosis), nephrotic syndrome, severe protein malnutrition, or protein-losing enteropathy.

Clinical Definition & Staging of Acute Liver Failure (ALF)

Acute Liver Failure (historically termed fulminant hepatic failure) is a catastrophic medical emergency defined by the simultaneous presence of three criteria :

• Severe Acute Liver Injury (massive transaminitis and hyperbilirubinemia);
• Coagulopathy with an INR >= 1.5 ;
• Hepatic Encephalopathy (altered mental status, confusion, asterixis, stupor, or coma);

Occurring in a patient WITHOUT pre-existing cirrhosis with an illness duration of less than 26 weeks . ACUTE LIVER FAILURE TEMPORAL SUBTYPES

• [Hyperacute: <7 Days] ───────> APAP Overdose, Ischemic Hepatitis, HAV
• Explosive transaminitis, rapid onset encephalopathy
• High risk of cerebral edema; good transplant-free recovery

• [Acute: 7 to 21 Days] ───────> Acute Hepatitis B Infection
• Moderate cerebral edema risk; intermediate prognosis

• [Subacute: 4 to 26 Weeks] ───> Idiosyncratic DILI, Autoimmune Hepatitis
• Insidious jaundice, low transaminases, late encephalopathy
• Low cerebral edema risk; exceptionally POOR survival (<20%)
• without emergency liver transplantation
• Critical Management Principles in Acute Liver Failure

Immediate Transfer to a Liver Transplant Center ICU : Delay in transfer is the leading cause of preventable death in ALF.

Cerebral Edema & Intracranial Hypertension (Leading Cause of Death in ALF) :

Severe hyperammonemia (>150-200 mcmol/L) results in excessive glutamine accumulation inside cerebral astrocytes, driving osmotic swelling, cerebral edema, intracranial hypertension, and fatal brainstem herniation.

Management: Elevate head of bed 30 degrees; maintain serum sodium at 145 to 150 mEq/L with 3% hypertonic saline ; administer IV mannitol (0.5–1.0 g/kg) for acute intracranial pressure (ICP) spikes; avoid hypercapnia and hypoxemia.

Metabolic Derangements : Check point-of-care blood glucose hourly; profound hypoglycemia occurs rapidly due to impaired gluconeogenesis and depleted glycogen stores; requires continuous IV 10% or 20% dextrose infusion.

Infection Prophylaxis : Broad-spectrum empiric IV antibiotics and antifungals; loss of hepatic reticuloendothelial clearance causes overwhelming bacteremia and fungemia.

N-Acetylcysteine (NAC) in Non-Acetaminophen ALF : Intravenous NAC has been proven to improve systemic hemodynamics, tissue microvascular perfusion, and transplant-free survival in early-stage non-acetaminophen ALF.

King's College Criteria for Emergency Liver Transplantation :

Acetaminophen ALF : Arterial pH <7.30 after fluid resuscitation, OR all three of: INR >6.5, serum creatinine >3.4 mg/dL, and Grade III/IV encephalopathy.

Non-Acetaminophen ALF : INR >6.5, OR any three of: etiology (idiosyncratic DILI, indeterminate), age <10 or >40 years, jaundice-to-encephalopathy interval >7 days, INR >3.5, serum bilirubin >17.5 mg/dL.

Acetaminophen (APAP) Hepatotoxicity & Management Protocols

Acetaminophen toxicity is the single most common cause of acute liver failure in the Western world, responsible for nearly 50% of all ALF cases in the United States.

Molecular Pathophysiology of APAP Hepatotoxicity

Normal Metabolism (Therapeutic Doses <=4 g/day) : 85% to 90% is safely conjugated via hepatic glucuronidation and sulfation into harmless, water-soluble metabolites excreted in urine.

Toxic Intermediate Generation : Approximately 5% to 10% is metabolized by cytochrome P450 enzymes (predominantly CYP2E1 ) into the highly reactive, electrophilic, toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) .

Glutathione Detoxification : Under normal conditions, intracellular glutathione immediately conjugates NAPQI into non-toxic mercapturic acid and cysteine compounds.

Overdose Cascade (>7.5 to 10 g in adults, or >150 mg/kg) : Primary glucuronidation and sulfation pathways become saturated, shunting massive amounts of APAP through CYP2E1. Once hepatic glutathione stores are depleted by >70% , free unneutralized NAPQI covalently binds to sulfhydryl groups on hepatocyte mitochondrial proteins. This triggers mitochondrial oxidative stress, loss of ATP production, mitochondrial permeability transition, and extensive centrilobular (Zone 3) hepatic necrosis (the zone of highest CYP2E1 expression and lowest oxygenation).

Potentiating Factors : Chronic alcohol use (induces CYP2E1 and depletes glutathione), malnutrition/fasting (depletes glutathione), and CYP2E1 inducers (phenytoin, carbamazepine, isoniazid).

The Four Clinical Phases of Acetaminophen Poisoning

Phase 1 (0 to 24 Hours) : Asymptomatic or non-specific mild nausea, vomiting, malaise, diaphoresis. Serum transaminases and bilirubin are completely normal.

Phase 2 (24 to 72 Hours) - 'The Latent Period' : Nausea improves, but subclinical hepatotoxicity begins: rising AST and ALT, RUQ abdominal pain, hepatomegaly, rising PT/INR, and acute kidney injury (from direct toxic tubular necrosis).

Phase 3 (72 to 96 Hours) - Peak Hepatotoxicity : Fulminant hepatic necrosis: severe jaundice, massive transaminitis (AST and ALT frequently exceed 10,000 to 20,000 U/L ), severe coagulopathy (INR >5 to 10), profound lactic acidosis, hypoglycemia, acute renal failure, and Stage III/IV hepatic encephalopathy.

Phase 4 (4 Days to 2 Weeks) - Recovery or Death : Complete hepatic regeneration over several weeks (without chronic fibrosis) in survivors, or death from multi-organ failure and cerebral edema.

The Rumack-Matthew Nomogram

Strictly validated ONLY for a single, acute ingestion of known timing presenting between 4 and 24 hours post-ingestion .

Cannot be used for chronic supratherapeutic ingestions, staggered doses, extended-release formulations, or ingestions presenting >24 hours later.

Timing Rule : A serum APAP level drawn before 4 hours post-ingestion cannot be interpreted , because gastrointestinal drug absorption is incomplete. The 4-hour serum level must be plotted on the nomogram.

Treatment Line : The treatment line begins at 150 mcg/mL (993 mcmol/L) at 4 hours post-ingestion and extends to 18.75 mcg/mL at 16 hours (incorporating a 25% safety buffer below the original 200 mcg/mL toxicity line). Any concentration on or above this 150 mcg/mL line mandates full antidote therapy.

Antidote Protocol: N-Acetylcysteine (NAC)

Mechanism of Action : NAC serves as a precursor for glutathione synthesis (providing cysteine) and directly binds and detoxifies NAPQI as a glutathione surrogate. In late presentations, NAC also acts as an antioxidant and microcirculatory vasodilator.

Efficacy Timing : NAC is most effective when administered within 8 hours of acute ingestion (reducing severe hepatotoxicity and mortality to near zero).

Crucial Clinical Rule : However, NAC MUST STILL BE ADMINISTERED AT ANY TIME if the patient presents >8 hours post-ingestion with an APAP level above the nomogram line, or if the patient presents late (>24 hours) with elevated transaminases or detectable APAP!

Treatment Regimens :

Intravenous (IV) NAC (21-Hour Protocol) :

• Loading dose: 150 mg/kg IV in 200 mL D5W over 60 minutes;
• Second dose: 50 mg/kg IV in 500 mL D5W over 4 hours;

Third dose: 100 mg/kg IV in 1,000 mL D5W over 16 hours.

Adverse Effect : Anaphylactoid Reaction (non-IgE-mediated histamine release causing flushing, urticaria, angioedema, or bronchospasm in up to 10-15% of patients, typically during the initial high-concentration loading dose). Management: temporarily stop infusion, administer IV diphenhydramine (and epinephrine if bronchospasm/shock), and resume the infusion at a slower rate once symptoms resolve.

Oral NAC (72-Hour Protocol) :

Loading dose: 140 mg/kg orally; followed by 70 mg/kg orally every 4 hours for 17 maintenance doses (total 72 hours). Pre-treat with antiemetics (ondansetron).

Stopping Criteria : NAC must NOT be discontinued blindly at 21 or 72 hours. Continue NAC until: 1) Serum APAP is undetectable; 2) AST and ALT are normal or clearly declining substantially; and 3) INR is <1.5 and renal function is stable.

• Acute Viral Hepatitis Spectrum: Serologies & Management
• Hepatitis A Virus (HAV)

Virology & Transmission : Non-enveloped RNA picornavirus transmitted via the fecal-oral route through contaminated food or water, raw shellfish, international travel to endemic nations, daycare exposure, or sexual contact (MSM). Incubation period: 15 to 50 days (mean 28 days).

Clinical Features : Acute, self-limited febrile illness with jaundice, dark urine (bilirubinuria), acholic stools, and RUQ tenderness. Children <6 years are typically anicteric (70%), whereas adults are symptomatic with jaundice (>70%).

Chronicity & Complications : HAV NEVER causes chronic hepatitis, cirrhosis, or hepatocellular carcinoma! Fulminant liver failure occurs in <0.5% (higher in older adults or underlying liver disease).

Serologic Interpretation :

Anti-HAV IgM : Positive at symptom onset, peaks during acute phase, and persists for 3 to 6 months. Confirms acute Hepatitis A infection .

Anti-HAV IgG : Appears soon after IgM and persists for life. Confirms past natural infection or vaccination , conferring lifelong immunity.

Post-Exposure Prophylaxis (PEP) : Must be administered within 14 days of exposure :

Healthy individuals aged 12 months to 40 years : Single dose of Hepatitis A vaccine .

Infants <12 months, adults >40 years, immunocompromised, or chronic liver disease : Hepatitis A Immune Globulin (IG, 0.1 mL/kg) (or vaccine + IG in high-risk individuals >40 years).

Hepatitis B Virus (HBV)

Virology & Transmission : Partially double-stranded circular DNA hepadnavirus transmitted parenterally (percutaneous blood contact, needle sharing), sexually, or perinatally (vertical transmission). Incubation period: 45 to 160 days (mean 90 days).

Age-Dependent Risk of Chronicity (Critical Board Concept) :

Neonates (Perinatal Transmission) : 90% develop chronic Hepatitis B infection (due to immune tolerance).

Children aged 1 to 5 years: 20% to 30% develop chronic HBV.

Immunocompetent Adults : Less than 5% develop chronic infection (>95% clear the virus and develop protective immunity).

Serologic Markers & Clinical Interpretation :

HBsAg (Surface Antigen) : First marker to appear. Indicates active infection (acute or chronic if persistent >6 months).

Anti-HBs (Surface Antibody) : Neutralizing antibody. Denotes immunity and viral clearance (titer >=10 mIU/mL from natural infection or vaccination).

Anti-HBc IgM (Core Antibody IgM) : Hallmark of acute Hepatitis B infection ! Present during acute illness and persists for 4 to 6 months.

The 'Window Period' : Interval between the disappearance of HBsAg and the appearance of detectable Anti-HBs. During this window, Anti-HBc IgM is the SOLE positive serologic marker of recent acute infection !

Anti-HBc IgG (Total Core Antibody) : Appears during acute infection and persists for life. Positive in anyone who experienced natural infection ; NEGATIVE in individuals immune via vaccination !

HBeAg (Envelope Antigen) : Marker of active, high viral replication and high infectivity.

Anti-HBe : Seroconversion denotes transition to lower replication.

HBV DNA : Quantitative viral load by PCR.

Comprehensive Hepatitis B Serology Matrix

• Clinical State HBsAg Anti-HBs Anti-HBc IgM Total Anti-HBc HBeAg HBV DNA
• Acute Hepatitis B Positive Negative Positive Positive Positive High
• Window Period Negative Negative Positive Positive Neg / Pos Low / Pos
• Resolved Natural Infection Negative Positive Negative Positive Negative Undetectable
• Vaccinated (Immune) Negative Positive Negative Negative Negative Undetectable
• Chronic Active HBV Positive (>6 mo) Negative Negative Positive Positive High (>20,000 IU/mL)
• Chronic Inactive Carrier Positive (>6 mo) Negative Negative Positive Negative (Anti-HBe +) Low (<2,000 IU/mL)

Management of Acute HBV : Supportive care in >95% of immunocompetent adults. Oral nucleos(t)ide analogues ( entecavir or tenofovir disoproxil fumarate / TAF ) are indicated ONLY for severe/fulminant acute HBV (coagulopathy INR >=1.5, severe protracted jaundice >4 weeks, or acute liver failure) .

Post-Exposure Prophylaxis (PEP) : Following percutaneous or mucosal exposure to an HBsAg-positive source:

Unvaccinated individual : Administer Hepatitis B Immune Globulin (HBIG) PLUS the first dose of the Hepatitis B vaccine series within 24 hours .

Previously vaccinated individual with documented anti-HBs >=10 mIU/mL : No prophylaxis or treatment required (patient is fully immune).

Hepatitis C Virus (HCV)

Virology & Transmission : Enveloped single-stranded RNA flavivirus transmitted primarily through blood (injection drug use, unsterilized tattoos, transfusions before 1992). Incubation period: 2 to 26 weeks.

Natural History : Acute HCV is asymptomatic in 70% to 80% of cases. Spontaneous clearance occurs in only 15% to 25% of individuals; 75% to 85% develop chronic Hepatitis C infection , which slowly progresses over decades to cirrhosis (in 20%) and hepatocellular carcinoma.

Diagnostic Testing Algorithm :

Screen with Anti-HCV antibody . If positive, reflex immediately to quantitative HCV RNA PCR .

Positive Anti-HCV + Positive HCV RNA = Active HCV Infection (acute or chronic).

Positive Anti-HCV + Negative HCV RNA = Resolved past infection or successfully cured HCV.

Management of Acute HCV : Monitor quantitative HCV RNA PCR for 12 to 16 weeks following diagnosis to allow for spontaneous clearance. If HCV RNA remains detectable after 12 to 16 weeks, initiate pan-genotypic Direct-Acting Antivirals ( glecaprevir-pibrentasvir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks ), achieving cure rates (SVR) >95% to 98%.

Hepatitis D Virus (HDV, 'Delta Agent')

Defective circular RNA virus that is obligate dependent on Hepatitis B virus : requires HBsAg to synthesize its viral envelope coat. It cannot infect in the absence of HBV.

Modes of Infection :

Coinfection : Simultaneous acquisition of HBV and HDV. Causes severe acute hepatitis, but chronicity is low (<5%, matching HBV clearance in adults).

Superinfection : Acute HDV infection acquired by a chronic HBsAg carrier. Triggers severe acute decompensation and carries a catastrophic 70% to 80% rate of rapid progression to cirrhosis and liver failure.

Prevention : Hepatitis B vaccination completely prevents Hepatitis D infection!

Hepatitis E Virus (HEV)

Non-enveloped RNA hepevirus. Genotypes 1 and 2 are transmitted enterically via the fecal-oral route through contaminated drinking water in developing nations (large epidemics in South/East Asia and Africa). Genotypes 3 and 4 are zoonotic in developed nations, transmitted via undercooked pork, wild boar, or deer meat.

Usually causes an acute, self-limited hepatitis similar to HAV with zero progression to chronicity in immunocompetent hosts.

Caution

CRITICAL BOARD EXAM PEARL: CATASTROPHIC HEV MORTALITY IN PREGNANCY In pregnant women—particularly during the third trimester —acute Hepatitis E infection (specifically Genotypes 1 and 2) carries an extraordinary and alarming 15% to 25% mortality rate due to rapidly progressive fulminant hepatic failure, obstetric hemorrhage, and eclampsia. Any pregnant woman returning from an endemic developing region (e.g., South Asia) presenting with acute severe jaundice, acute liver failure, and negative HAV, HBV, and HCV serologies has acute Hepatitis E infection until proven otherwise!

Loading diagram... Acute Liver Injury Patterns & Hepatitis B Serology Matrix